Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is listed and traded on the New York Stock Exchange under the symbol “DGX.” As of February 2, 2026, we had approximately 1,881 record holders of our common stock; we believe that the number of beneficial holders of our common stock exceeds the number of record holders.
The table below sets forth the information with respect to purchases made by or on behalf of the Company of its common stock during the fourth quarter of 2025.
ISSUER PURCHASES OF EQUITY SECURITIES
Period Total Number of
Shares
Purchased Average Price
Paid per Share Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the Plans
or Programs
(in thousands)
October 1, 2025 – October 31, 2025
Share Repurchase Program (A)(C) 450,702 $ 179.58 450,702 $ 654,985
Employee Transactions (B) — $ — N/A N/A
November 1, 2025 – November 30, 2025
Share Repurchase Program (A)(C) 940,277 $ 185.12 940,277 $ 480,920
Employee Transactions (B) 8,938 $ 177.74 N/A N/A
December 1, 2025 – December 31, 2025
Share Repurchase Program (A)(C) 246,212 $ 182.77 246,212 $ 435,921
Employee Transactions (B) 695 $ 183.04 N/A N/A
Total
Share Repurchase Program (A)(C) 1,637,191 $ 183.24 1,637,191 $ 435,921
Employee Transactions (B) 9,633 $ 178.12 N/A N/A
(A) As of December 31, 2025, $0.4 billion remained available under our share repurchase authorization. In February 2026, our Board of Directors increased the size of our share repurchase program by $1 billion to $1.4 billion. The share repurchase authorization has no set expiration or termination date. Since the share repurchase program's inception in May 2003, our Board of Directors has authorized $14 billion of share repurchases of our common stock.
(B) Includes: (1) shares delivered or attested to in satisfaction of the exercise price and/or tax withholding obligations by holders of stock options (granted under the Company's Amended and Restated Employee Long-Term Incentive Plan) who exercised options; and (2) shares withheld (under the terms of grants under the Amended and Restated Employee Long-Term Incentive Plan) to offset tax withholding obligations that occur upon the delivery of outstanding common shares underlying restricted share units and performance share units.
(C) Excludes excise taxes on share repurchases of $2 million in aggregate, which will be paid in 2026.
45
Table of Contents
Performance Graph
Set forth below is a line graph comparing the cumulative total shareholder return on Quest Diagnostics' common stock since December 31, 2020 based on the market price of the Company's common stock and assuming reinvestment of dividends, with the cumulative total shareholder return of companies on the Standard & Poor's (S&P) 500 Stock Index and the S&P 500 Health Care (Sector) Index.
Closing DGX Price Total Shareholder Return Performance Graph Values
Date DGX S&P 500 S&P 500 Health Care (Sector) DGX S&P 500 S&P 500 Health Care (Sector)
12/31/2021 $ 173.01 47.86 % 28.71 % 26.13 % $ 147.86 $ 128.71 $ 126.13
12/30/2022 $ 156.44 (7.79) % (18.13) % (1.95) % $ 136.34 $ 105.37 $ 123.67
12/29/2023 $ 137.88 (10.05) % 26.29 % 2.06 % $ 122.64 $ 133.07 $ 126.22
12/31/2024 $ 150.86 11.77 % 25.02 % 2.58 % $ 137.07 $ 166.37 $ 129.48
12/31/2025 $ 173.53 17.20 % 17.88 % 14.60 % $ 160.65 $ 196.11 $ 148.37
Item 6 [Reserved]
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
See page 59 .
46
Table of Contents
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
See Management's Discussion and Analysis of Financial Condition and Results of Operations.
Item 8. Financial Statements and Supplementary Data
See Item 15(a)1 and Item 15(a)2.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.